AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06653829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPARK
Description: A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
Study NCT06653881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARCHWIRE
Description: Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
Study NCT06652633 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG CAR T-cell therapy
Description: No investigational products will be administered to participants in this study.
Study NCT06593366 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplant
Description: An investigational biologic comprised of 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule, to be taken twice per day, twice per week over an 8-week duration.
Study NCT06593366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
Study NCT05572814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Support
Description: Prompts will be provided to clinicians signaling gaps in guideline-directed care
Study NCT05572814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral
Description: Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
Study NCT06130839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocker board training
Description: Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
Study NCT06130839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable surface training
Description: the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
Study NCT06613412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Remote Robotic Bronchoscopy system
Description: Utilization of a remote robotic bronchoscopy system for the biopsy of patients with pulmonary peripheral lesions
Study NCT05413395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical colloidal oatmeal formulation with a modified plant oil
Description: Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties.
Study NCT05413395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical colloidal oatmeal formulation
Description: Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
Study NCT06269965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regeneten® adding
Description: Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
Study NCT04718272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic drainage management
Description: After uniportal VATS pulmonary lobectomy, the traditional silicone tube which placed through the surgical incision was removed in the operating room in the experimental group.
Study NCT04365829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality headset Occulus GO
Description: Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO.
Study NCT05649423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POSTURAL DRAINAGE WITH PERCUSSION
Description: Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal.
Study NCT05649423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural drainage
Description: * Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs.
Study NCT05649423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural drainage
Description: * Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs.
Study NCT06432010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group nutrition and physical activity coaching
Description: Group nutrition and physical activity coaching consists of an initial health check-up, followed by nutrition and physical activity coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the group nutrition and physical activity coaching sessions.
Study NCT06432010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group cognition coaching
Description: Group cognition coaching consists of an initial health check-up, followed by cognition coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the cognition coaching sessions.
Study NCT05394831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JIN-A02
Description: PO, QD
Study NCT05990608 — intervention group
Intervention type: OTHER
Intervention: Peabody Developmental Motor Scales-2, PDMS
Description: The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high.
Study NCT05276869 — intervention group
Intervention type: OTHER
Intervention: WeeFIM instrument
Description: In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create \[10\].
Study NCT05482217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)
Description: The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks.
Study NCT05474014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior trunk block
Description: Local anesthetic injection will be applied to the superior trunk of the brachial plexus accompanied by ultrasonography.
Study NCT05474014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous patient-controlled analgesia
Description: Analgesics will be given using a patient-controlled analgesia device.
Study NCT05839444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioPB-01
Description: 2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
Study NCT05839444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
Study NCT05628610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg d1, Q3W
Study NCT05628610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy dose: 5,000 c G y / 30f
Study NCT05628610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: 150mg / m2 ,d1, q3w
Study NCT05628610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs
Description: cisplatin, carboplatin, naidaplatin and other platinum drugs
Study NCT06520618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qing Re He Ji
Description: Oral administration of Qing Re He Ji
Study NCT06520618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shuanghuanglian Oral Liquid
Description: Oral administration of Shuanghuanglian Oral Liquid
Study NCT05553821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold sand bag
Description: A sand bag weighing 3.5-4 kg is applied to the CAG area of patients.
Study NCT05553821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A sand bag
Description: A sand bag
Study NCT06206304 — intervention group
Intervention type: OTHER
Intervention: Root canal therapy
Description: Traditional root canal therapy was performed with rubber-dam isolation.
Study NCT04885517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal catheter
Description: Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
Study NCT05339542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: derived from patient own blood
Study NCT05339542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MethylPREDNISolone 40 MG
Description: active comparative intervention
Study NCT05205824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: algorithm validation
Description: stroke subjects are measured to validate algorithms previously developed after including healthy subjects
Study NCT05932407 — intervention group
Intervention type: DRUG
Intervention: Vortioxetine Tablet
Description: Vortioxetine Tablet
Study NCT05932407 — intervention group
Intervention type: DRUG
Intervention: SSRI
Description: SSRI: Selective Serotonin Reuptake Inhibitor
Study NCT06538571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy
Description: Noninvasive monitor for venous saturation
Study NCT06519422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Tablets
Study NCT06519422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo tablets (inactive ingredients only, including microcrystalline cellulose, magnesium stearate BP and lactose)
Study NCT05914467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Description: Dose will be adjusted in the study arm using MIPD guided TDM- dosing
Study NCT04637282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX-200
Description: 15 mg/mL oral solution of experimental drug
Study NCT04637282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taste and color-matched drug-free solution
Study NCT05286580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morbidity and mortality conference toolkit
Description: * Standardized slide deck~* Code of conduct~* Conference planning checklist~* Case documentation form
Study NCT06602037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-DFO-SHR1920
Description: Enrolled pancreatic cancer patients will receive a single dose (1-3mCi) of \[89Zr\]Zr-DFO-SHR1920 (total 1-2mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
Study NCT06602037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-3A12
Description: Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[18F\]F-RESCA-3A12 injection.
Study NCT06602037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-3A12
Description: Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[68Ga\]Ga-NOTA-3A12 injection.
Study NCT05953194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to counter-marketing messages
Description: Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
Study NCT06623526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2402
Description: Test Drug: YHR2402
Study NCT06623526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2402+YHR2403
Description: Test Drug: YHR2402+YHR2403
Study NCT06628323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Intervention employing Neurofeedback
Description: Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia
Study NCT06628323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality-based Intervention
Description: Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia
Study NCT05953194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to traditional health messages
Description: Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
Study NCT05953194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to control (neutral) messages
Description: Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
Study NCT04878705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TWP-201
Description: a single subcutaneous injection
Study NCT06698263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.
Study NCT06698263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group (placebo)
Description: placebo administration
Study NCT04878705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a single subcutaneous injection
Study NCT05760794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-barbed delayed absorbable suture
Description: The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
Study NCT05760794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barbed delayed absorbable suture
Description: The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
Study NCT05989399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: circulating neutrophils
Description: evaluation of circulating neutrophils level
Study NCT06573658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT)
Description: It will be a two-session training with each session lasting for approximately half an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.
Study NCT06573658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control (control)
Description: It will be a two-session training with each session lasting for approximately half an hour. The same training duration and format will be used as the PBT group, except no perturbations will be induced during the treadmill walking.
Study NCT06696170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX nano-pFA 360 Endocardial Ablation Catheter System
Description: The CellFX nano-PFA 360 Endocardial Ablation Catheter System includes the nano-pFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures for the treatment of arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nano-second pulses of electrical energy. Nanosecond Pulsed Field Ablation (nsPFA or nano-PFA) is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the ability of the cell and internal organelles to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
Study NCT06700681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: TIVA induction and maintain with Propofol.
Study NCT06700681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: TIVA induction and maintain with Propofol.
Study NCT06700681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: TIVA induction and maintain with Remimazolam.
Study NCT06700681 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: With intubation and controlled ventilation to maintain airway
Description: Patient receives intubation and controlled ventilation to maintain airway.
Study NCT06700681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With intubation and controlled ventilation to maintain airway
Description: Patient receives intubation and controlled ventilation to maintain airway.